Ab­b­Vie’s $8.7B neu­ro gam­bit; Land­mark sick­le cell ap­provals; Roche buys a GLP-1 com­pa­ny; End­points 100 biotech ...

Last year
Weekly

As cash runs tight, blue­bird plunges af­ter pric­ing sick­le cell gene ther­a­py well above com­peti­tor and fail­ing to win ...

Last year
Pharma
Cell/Gene Tx

Ab­b­Vie teams with Parkin­son’s dis­ease foun­da­tion for 'Flip­ping the Switch' ef­fort

Last year
Pharma
Marketing

New re­search points to po­ten­tial link be­tween GLP-1s and low­ered risk of col­orec­tal can­cer

Last year
Pharma

Think phar­ma ads have too many celebri­ties and jin­gles? Not many ac­tu­al­ly use them, study finds

Last year
Pharma
Marketing

Roche touts full da­ta for drug in first-line PIK3CA-mu­tat­ed breast can­cer

Last year
R&D

Gavi an­nounces $1.8B for vac­cine ac­cess, pan­dem­ic pre­pared­ness ef­forts in Africa

Last year
R&D
Pharma

How one lab's decades­long search for the 'holy grail' of sick­le cell led to the first CRISPR ther­a­py

Last year
R&D
Cell/Gene Tx

FDA ap­proves two gene ther­a­pies for sick­le cell dis­ease, in­clud­ing first that us­es CRISPR

Last year
Pharma
FDA+

No­var­tis preps Kisqali for FDA; Ven­tyx cuts 20% of work­ers; Keytru­da plus Lenvi­ma hits PhI­II set­back

Last year
News Briefing

Bris­tol My­ers’ lead deal ne­go­tia­tor to de­part af­ter ink­ing se­ries of multi­bil­lion-dol­lar ac­qui­si­tions

Last year
People
Pharma

The End­points 100 sur­vey: Has biotech hit rock bot­tom?

Last year
Bioregnum

Fresh from re­brand, Spyre Ther­a­peu­tics rais­es $180M as it steers TLA1 pro­gram to clin­ic

Last year
Financing

Af­ter ink­ing re­verse merg­er, Graphite Bio di­vests gene edit­ing pipeline to new­ly-formed biotech

Last year
Startups
R&D

Ex-Cedil­la CEO Glucks­mann ex­plores ‘new fron­tier’ at Sen­so­ri­um; R&D chief out at Mer­ck women’s health spin­off ...

Last year
Peer Review

Sam Wak­sal's ROCK2 biotech Gravi­ton hauls in $35M boost from Ena­vate

Last year
Financing
Startups

Biden pro­pos­al on 'march-in' rights would have lim­it­ed ef­fect on cur­rent drug costs, crit­ics say

Last year
Pharma
FDA+

Sen. Klobuchar calls out Ris­ing Phar­ma for price-goug­ing an old gener­ic drug in short­age

Last year
Pharma

Physi­cians are start­ing to shift phar­ma sales rep mod­els from push to pull, study finds

Last year
Pharma
Marketing

Mer­ck halts tri­al af­ter Keytru­da-Lyn­parza com­bo flunks PhI­II study in lung can­cer

Last year
Pharma

House com­mit­tee ad­vances key PBM bills in step with Sen­ate coun­ter­parts

Last year
Pharma
FDA+

Van­da buys J&J's mul­ti­ple scle­ro­sis drug Pon­vory for $100M

Last year
Deals
Pharma

Sol­id tu­mor biotech’s poly­mer nanopar­ti­cle-drug con­ju­gate clears ear­ly-stage hur­dle, spark­ing PhII plans

Last year
R&D

Synaf­fix ex­pands In­novent deal; Re­ci­pharm co-de­vel­ops in­halers; Vit­riVax gets $5M for vac­cine tech

Last year
Manufacturing
First page Previous page 233234235236237238239 Next page Last page
A service from the Financial Times